National Heart, Lung, and Blood Institute; Notice of Closed Meetings, 43365-43366 [2023-14297]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 129 / Friday, July 7, 2023 / Notices
of U.S. ID is required for in-person
attendance.
ddrumheller on DSK120RN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Substantive program information may
be obtained from Rebecca Hines, MHS,
Executive Secretary, NCVHS, National
Center for Health Statistics, Centers for
Disease Control and Prevention, 3311
Toledo Road, Hyattsville, Maryland
20782, or via electronic mail to vgh4@
cdc.gov; or by telephone (301) 458–
4715. Summaries of meetings and a
roster of Committee members are
available on the NCVHS website https://
ncvhs.hhs.gov/, where further
information including an agenda and
instructions to access the broadcast of
the meeting will be posted.
Should you require reasonable
accommodation, please telephone the
CDC Office of Equal Employment
Opportunity at (770) 488–3210 as soon
as possible.
SUPPLEMENTARY INFORMATION:
Purpose: As outlined in its Charter,
the National Committee on Vital and
Health Statistics assists and advises the
Secretary of HHS on health data, data
standards, statistics, privacy, national
health information policy, and the
Department’s strategy to best address
those issues.1 Under the Health
Insurance Portability and
Accountability Act of 1996 (HIPAA),2
NCVHS advises the Secretary on
administrative simplification standards,
including those for privacy, security,
adoption and implementation of
transaction standards, unique
identifiers, code sets, and operating
rules adopted under the Patient
Protection and Affordable Care Act
(ACA).3
The meeting agenda will include time
to introduce six new members recently
appointed to serve on the Committee,
continue with activities outlined in the
NCVHS 2023 workplan, and hold
discussions on several health data
policy topics, including a briefing on
conversational artificial intelligence
(AI).
The NCVHS Workgroup on Timely
and Strategic Action to Inform ICD–11
Policy for morbidity will report to the
full Committee on activities leading up
to the August 3, 2023, Expert
Roundtable meeting. The National
Center for Health Statistics will provide
an update on implementation of ICD–11
for mortality.
1 The original authorities of NCVHS are described
at 42 U.S. Code § 242k.
2 Public Law 104–191, 110 Stat. 1936 (Aug 21,
1996), available at https://www.congress.gov/104/
plaws/publ191/PLAW-104publ191.pdf.
3 Public Law 111–148, 124 Stat. 119 (Mar. 23,
2010), available at https://www.congress.gov/111/
plaws/publ148/PLAW-111publ148.pdf.
VerDate Sep<11>2014
18:55 Jul 06, 2023
Jkt 259001
The Subcommittee on Privacy,
Confidentiality and Security will host
panel briefings on Privacy and
Reproductive Health with invited
experts. The Subcommittee on
Standards will report on its
‘‘Convergence 2.0’’ activities in light of
completion of recommendations to the
Department approved at the June 14,
2023, meeting of the full Committee.
Finally, the Committee will allot time to
discuss language for inclusion in the
Committee’s 2023 Report to Congress.
The Committee will reserve time on
the agenda for public comment. Meeting
times and topics are subject to change.
Please refer to the agenda posted on the
NCVHS website for updates: https://
ncvhs.hhs.gov/meetings/full-committeemeeting-14/.
Sharon Arnold,
Associate Deputy Assistant Secretary, Office
of Science and Data Policy, Office of the
Assistant Secretary for Planning and
Evaluation.
[FR Doc. 2023–14284 Filed 7–6–23; 8:45 am]
BILLING CODE 4150–05–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Mentored Career Development Awards.
Date: August 2, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Kristin Goltry, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 209–B,
Bethesda, MD 20892, (301) 435–0297,
goltrykl@mail.nih.gov.
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
43365
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Emerging Investigator Award (R35
EIA) Review Meeting.
Date: August 3, 2023.
Time: 10:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Kazuyo Kegan, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 208–T,
Bethesda, MD 20892, (301) 402–1334,
kazuyo.kegan@nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Mentored Career Development KAwards.
Date: August 3, 2023.
Time: 10:30 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Fungai Chanetsa, Ph.D.,
MPH, Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes
of Health, 6705 Rockledge Drive, Room 206–
B, Bethesda, MD 20817, (301) 402–9394,
fungai.chanetsa@nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Catalyze Enabling Technologies.
Date: August 4, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Kristin Goltry, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 209–B,
Bethesda, MD 20892, (301) 435–0297,
goltrykl@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Catalyze Product Definition.
Date: August 7, 2023.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Kristin Goltry, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 209–B,
Bethesda, MD 20892, (301) 435–0297,
goltrykl@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
E:\FR\FM\07JYN1.SGM
07JYN1
43366
Federal Register / Vol. 88, No. 129 / Friday, July 7, 2023 / Notices
and Resources Research, National Institutes
of Health, HHS)
Dated: June 30, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–14297 Filed 7–6–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852 by contacting
Chris Kornak at 240–627–3705 or
chris.kornak@nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished information related to the
invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
Dual-Germline Antibody Engager
Chimeric HIV–1 Immunogens
Description of Technology: Despite
four decades of intensive research, a
safe and effective HIV–1 vaccine
remains elusive due to the extreme
difficulty in eliciting broadly
neutralizing antibodies (bNAbs), which
recognize and block HIV–1 from
entering healthy cells. Only rare natural
HIV–1 envelopes (Envs) promote the
activation and expansion of naı¨ve B
cells expressing unmutated germline
antibodies of various bNAb lineages, but
they typically do so for a single lineage
for the same neutralization site. To
overcome this challenge, NIAID has
designed and characterized two
chimeric HIV–1 Env immunogens
capable of simultaneously engaging
VerDate Sep<11>2014
18:55 Jul 06, 2023
Jkt 259001
multiple germline bNAb lineages. Both
chimeric Env immunogens maintain
native-like folding and engage two
lineages of germline bNAbs directed
against two independent sites of HIV–1
vulnerability.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Immunization: The dual-germline
engager HIV–1 immunogens could be
employed during the priming phase of
an HIV vaccine to trigger multiple bNAb
lineages simultaneously, resulting in a
multi-target protective antibody
response.
• Clinical Treatment: The dualgermline engager HIV–1 immunogens
could serve as an alternative to current
anti-retrovirals or incorporated into
current HIV treatment strategies.
Competitive Advantages:
• Dual-germline engager HIV–1 Env
immunogens are inherently superior to
the currently available single-germline
engagers for eliciting bNAbs.
• The chimeric design could be
expanded to generate HIV–1 Env trimers
with even more germline bNAb
specificities to enable a broader
immunogenic response against HIV.
Inventors: Peng Zhang, Ph.D., Paolo
Lusso, M.D., Ph.D., both of NIAID.
Publications: Publication pending.
Intellectual Property: HHS Reference
No. E–140–2022; US Provisional
Application No. 63/397,789.
Licensing Contact: To license this
technology, please contact Chris Kornak
at 240–627–3705 or chris.kornak@
nih.gov, and reference E–140–2022.
Collaborative Research Opportunity:
The Technology Transfer and
Intellectual Property Office is seeking
parties interested in collaborative
research to further develop this
technology by manufacturing nonMRNA virus-like particles incorporating
dual germline engager HIV–1
immunogens and subsequently testing
immunogenicity in non-human
primates. For collaboration
opportunities, please contact Chris
Kornak; 240–627–3705, chris.kornak@
nih.gov.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2023–14308 Filed 7–6–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Social
Sciences and Population Studies A:
Additional Applications.
Date: July 31, 2023.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Suzanne Ryan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, (301) 435–
1712, ryansj@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 30, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–14323 Filed 7–6–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\07JYN1.SGM
07JYN1
]]>Agencies
[Federal Register Volume 88, Number 129 (Friday, July 7, 2023)]
[Notices]
[Pages 43365-43366]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-14297]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Mentored Career Development Awards.
Date: August 2, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge I, 6705
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kristin Goltry, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 209-B, Bethesda, MD 20892, (301) 435-0297,
[email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; NHLBI Emerging Investigator Award (R35 EIA)
Review Meeting.
Date: August 3, 2023.
Time: 10:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge I, 6705
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kazuyo Kegan, Ph.D., Scientific Review Officer,
Office of Scientific Review/DERA, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6705 Rockledge Drive, Room
208-T, Bethesda, MD 20892, (301) 402-1334, [email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; NHLBI Mentored Career Development K-Awards.
Date: August 3, 2023.
Time: 10:30 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge I, 6705
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Fungai Chanetsa, Ph.D., MPH, Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 206-B, Bethesda, MD 20817, (301) 402-9394,
[email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Catalyze Enabling Technologies.
Date: August 4, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge I, 6705
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kristin Goltry, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 209-B, Bethesda, MD 20892, (301) 435-0297,
[email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Catalyze Product Definition.
Date: August 7, 2023.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge I, 6705
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kristin Goltry, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 209-B, Bethesda, MD 20892, (301) 435-0297,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases
[[Page 43366]]
and Resources Research, National Institutes of Health, HHS)
Dated: June 30, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-14297 Filed 7-6-23; 8:45 am]
BILLING CODE 4140-01-P
